02.06.2017 • NewsThermo FisherPatheonM%26A

Thermo Fisher to Buy Patheon for $7.2 Billion

Laboratory supplies giant Thermo Fisher Scientific announced plans to buy contract development and manufacturing organization (CDMO) Patheon for $35.00 per share in cash. The transaction totals approximately $7.2 billion, which includes the assumption of approximately $2 billion of net debt and is expected to be completed by the end of 2017.

As the laboratory supply sector continues to consolidate, the larger providers are seeking to provide more comprehensive services. This deal, agreed by both firms’ boards, gives Thermo Fisher a ready-made platform in the rapidly-growing area of contract development and manufacturing, to go alongside its existing laboratory products and services business. Thermo expects to be able to save $90 million in costs after three years.

Patheon has a network of facilities, primarily in North America and Europe, and approximately 9.000 professionals worldwide. In 2016, the company generated approximately $1.9 billion in revenue and will become part of Thermo Fisher's Laboratory Products and Services Segment, the companies said in a press release about the acquisition.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.